These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 24617622)
1. Is TOF normalization suitable on daily clinical practice? In reply. Pompei L; Della Rocca G Acta Anaesthesiol Scand; 2014 Apr; 58(4):497-9. PubMed ID: 24617622 [No Abstract] [Full Text] [Related]
2. Recovery times after sugammadex: is the data flawed? Kopman AF Acta Anaesthesiol Scand; 2014 Apr; 58(4):496-7. PubMed ID: 24400790 [No Abstract] [Full Text] [Related]
3. Reversal of rocuronium induced neuromuscular block with sugammadex or neostigmine: a large observational study. Della Rocca G; Pompei L; Pagan DE Paganis C; Tesoro S; Mendola C; Boninsegni P; Tempia A; Manstretta S; Zamidei L; Gratarola A; Murabito P; Fuggiano L; DI Marco P Acta Anaesthesiol Scand; 2013 Oct; 57(9):1138-45. PubMed ID: 23849107 [TBL] [Abstract][Full Text] [Related]
4. Antagonism of profound cisatracurium and rocuronium block: the role of objective assessment of neuromuscular function. Kopman AF; Kopman DJ; Ng J; Zank LM J Clin Anesth; 2005 Feb; 17(1):30-5. PubMed ID: 15721727 [TBL] [Abstract][Full Text] [Related]
5. Sugammadex in a parturient with myotonic dystrophy. Stourac P; Krikava I; Seidlova J; Strazevska E; Huser M; Hruban L; Janku P; Gal R Br J Anaesth; 2013 Apr; 110(4):657-8. PubMed ID: 23508494 [No Abstract] [Full Text] [Related]
6. [Sugammadex reversal of neuromuscular blockade for thymectomy in a patient with myasthenia gravis]. Monsalve Naharro JA; Gerónimo Pardo M; Ortiz Sánchez VE; Pérez Valdivieso JM Rev Esp Anestesiol Reanim; 2011 Dec; 58(10):624-5. PubMed ID: 22263413 [No Abstract] [Full Text] [Related]
8. Do we really need sugammadex as an antagonist of muscle relaxants in anesthesia? Meistelman C; Donati F Curr Opin Anaesthesiol; 2016 Aug; 29(4):462-7. PubMed ID: 27168088 [TBL] [Abstract][Full Text] [Related]
9. In reply. Pongrácz A; Nemes R; Fülesdi B; Tassonyi E Anesthesiology; 2014 Feb; 120(2):508-9. PubMed ID: 24448083 [No Abstract] [Full Text] [Related]
10. Safety of Sugammadex for Neuromuscular Reversal in Cardiac Transplant Patients. Varela N; Golvano M; Pérez-Pevida B J Cardiothorac Vasc Anesth; 2016 Aug; 30(4):e37. PubMed ID: 27222050 [No Abstract] [Full Text] [Related]
11. Reasoning of an anomaly: residual block after sugammadex. Naguib M; Brull SJ; Arkes HR Anesth Analg; 2013 Aug; 117(2):297-300. PubMed ID: 23881373 [No Abstract] [Full Text] [Related]
14. Why are we using pulse oximetry but not neuromuscular monitoring routinely: the real world scenario? de Boer HD; Booij LH Anesth Analg; 2014 Mar; 118(3):690. PubMed ID: 24557114 [No Abstract] [Full Text] [Related]
15. Sugammadex: a novel agent for the reversal of neuromuscular blockade. Nicholson WT; Sprung J; Jankowski CJ Pharmacotherapy; 2007 Aug; 27(8):1181-8. PubMed ID: 17655516 [TBL] [Abstract][Full Text] [Related]
16. A novel approach to reversal of neuromuscular blockade. Della Rocca G; Pompei L Minerva Anestesiol; 2009 May; 75(5):349-51. PubMed ID: 19412157 [TBL] [Abstract][Full Text] [Related]
17. A randomised controlled trial comparing sugammadex and neostigmine at different depths of neuromuscular blockade in patients undergoing laparoscopic surgery. Geldner G; Niskanen M; Laurila P; Mizikov V; Hübler M; Beck G; Rietbergen H; Nicolayenko E Anaesthesia; 2012 Sep; 67(9):991-8. PubMed ID: 22698066 [TBL] [Abstract][Full Text] [Related]